Drug news
FDA accepts filing of Zohydro ER for Chronic Pain treatment
The FDA has accepted for review the new drug application (NDA) for the oral, extended-release hydrocodone therapy ZohydroER from Zogenix Inc., as a treatment for moderate to severe Chronic Pain.The FDA set 1 March 2013 as the Prescription Drug User Fee Act action date � granting a 10-month standard review.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.